Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

Abstract Objective To evaluate the safety and efficacy of intravenous golimumab + methotrexate (MTX) in patients with active rheumatoid arthritis (RA) aged < 65 years and those ≥ 65 years who were enrolled in the GO-FURTHER study. Methods In the phase III, double-blind, randomized, placebo-contro...

Full description

Bibliographic Details
Main Authors: John Tesser, Shelly Kafka, Raphael J. DeHoratius, Stephen Xu, Elizabeth C. Hsia, Anthony Turkiewicz
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Geriatric
Anti-tumor necrosis factor
Golimumab
Online Access:http://link.springer.com/article/10.1186/s13075-019-1968-x

Internet

http://link.springer.com/article/10.1186/s13075-019-1968-x

Similar Items